Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
Issuer Blackrock
Entity holding fund iShares IV Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF Ticker BTEC(USD) LSE
ETF Ticker BTEK(GBP) LSE
ETF Ticker 2B70(EUR) F
ETF Ticker 2B70.DE(EUR) CXE
ETF Ticker BTEC.LS(USD) CXE
ETF Ticker BTEK.LS(GBP) CXE
ETF Ticker BTEC.L(GBP) LSE
ETF Ticker BTEK.L(GBP) LSE

Holdings detail for PRTA

Stock Name	Prothena Corporation plc
Ticker	PRTA(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	IE00B91XRN20

Show aggregate PRTA holdings

News associated with PRTA

Prothena Corporation plc (NASDAQ:PRTA) Receives $30.25 Average PT from Brokerages: Shares of Prothena Corporation plc (NASDAQ:PRTA – Get Free Report) have received a consensus rating of “Hold” from the nine brokerages that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and four have issued a buy recommendation on […] - 2025-08-19 04:26:55
Chicago Partners Investment Group LLC Buys 3,315 Shares of Prothena Corporation plc (NASDAQ:PRTA): Chicago Partners Investment Group LLC grew its holdings in Prothena Corporation plc (NASDAQ:PRTA – Free Report) by 29.6% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 14,512 shares of the biotechnology company’s stock after buying an additional 3,315 shares during the period. Chicago […] - 2025-08-13 05:18:49
TD Asset Management Inc Reduces Stock Position in Prothena Corporation plc (NASDAQ:PRTA): TD Asset Management Inc cut its stake in Prothena Corporation plc (NASDAQ:PRTA – Free Report) by 3.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 62,694 shares of the biotechnology company’s stock after selling 2,000 shares during the period. TD Asset Management […] - 2025-08-05 04:37:17
Brokerages Set Prothena Corporation plc (NASDAQ:PRTA) Target Price at $31.50: Prothena Corporation plc (NASDAQ:PRTA – Get Free Report) has earned an average recommendation of “Hold” from the nine analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and four have issued a buy recommendation on the company. […] - 2025-07-25 05:12:48
Alps Advisors Inc. Has $470,000 Stake in Prothena Corporation plc (NASDAQ:PRTA): Alps Advisors Inc. trimmed its position in shares of Prothena Corporation plc (NASDAQ:PRTA – Free Report) by 12.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 37,956 shares of the biotechnology company’s stock after selling 5,554 shares during the period. Alps Advisors Inc. […] - 2025-07-15 06:59:50
Cambridge Investment Research Advisors Inc. Acquires New Stake in Prothena Corporation plc (NASDAQ:PRTA): Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Prothena Corporation plc (NASDAQ:PRTA – Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 10,164 shares of the biotechnology company’s stock, valued at approximately $126,000. A number of […] - 2025-07-15 04:17:25
SG Americas Securities LLC Raises Stock Holdings in Prothena Corporation plc (NASDAQ:PRTA): SG Americas Securities LLC increased its position in Prothena Corporation plc (NASDAQ:PRTA – Free Report) by 92.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 72,559 shares of the biotechnology company’s stock after acquiring an additional 34,947 shares during the period. SG […] - 2025-06-19 04:30:54
Prothena Co. plc (NASDAQ:PRTA) Shares Acquired by Two Sigma Investments LP: Two Sigma Investments LP increased its stake in Prothena Co. plc (NASDAQ:PRTA – Free Report) by 265.4% during the 4th quarter, Holdings Channel reports. The fund owned 38,394 shares of the biotechnology company’s stock after purchasing an additional 27,887 shares during the quarter. Two Sigma Investments LP’s holdings in Prothena were worth $532,000 as of […] - 2025-06-09 04:30:53
Hennion & Walsh Asset Management Inc. Buys 25,353 Shares of Prothena Co. plc (NASDAQ:PRTA): Hennion & Walsh Asset Management Inc. lifted its holdings in Prothena Co. plc (NASDAQ:PRTA – Free Report) by 48.5% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 77,637 shares of the biotechnology company’s stock after purchasing an additional 25,353 shares during the period. Hennion & Walsh Asset […] - 2025-06-08 05:53:06
Bank of America Corp DE Acquires 36,944 Shares of Prothena Co. plc (NASDAQ:PRTA): Bank of America Corp DE increased its holdings in shares of Prothena Co. plc (NASDAQ:PRTA – Free Report) by 45.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 119,007 shares of the biotechnology company’s stock after buying an additional 36,944 shares […] - 2025-06-05 05:14:52
Prothena (NASDAQ:PRTA) Earns “Underperform” Rating from Bank of America: Prothena (NASDAQ:PRTA – Get Free Report)‘s stock had its “underperform” rating restated by stock analysts at Bank of America in a research report issued to clients and investors on Wednesday, MarketBeat.com reports. A number of other analysts have also recently weighed in on PRTA. Cantor Fitzgerald cut shares of Prothena from an “overweight” rating to […] - 2025-05-30 05:06:52
Bank of America Reaffirms Underperform Rating for Prothena (NASDAQ:PRTA): Prothena (NASDAQ:PRTA – Get Free Report)‘s stock had its “underperform” rating restated by research analysts at Bank of America in a note issued to investors on Wednesday, MarketBeat.com reports. A number of other equities analysts have also issued reports on PRTA. Cantor Fitzgerald lowered shares of Prothena from an “overweight” rating to a “neutral” rating […] - 2025-05-30 05:06:52
Prothena (NASDAQ:PRTA) Receives “Underperform” Rating from Bank of America: Prothena (NASDAQ:PRTA – Get Free Report)‘s stock had its “underperform” rating reiterated by Bank of America in a research note issued to investors on Wednesday, Marketbeat Ratings reports. PRTA has been the topic of several other reports. Cantor Fitzgerald cut shares of Prothena from an “overweight” rating to a “neutral” rating in a report on […] - 2025-05-30 05:06:52
Prothena (NASDAQ:PRTA) Given Underperform Rating at Bank of America: Prothena (NASDAQ:PRTA – Get Free Report)‘s stock had its “underperform” rating reiterated by stock analysts at Bank of America in a note issued to investors on Wednesday, MarketBeat.com reports. PRTA has been the topic of a number of other reports. Wall Street Zen upgraded Prothena from a “sell” rating to a “hold” rating in a […] - 2025-05-30 05:06:52
Prothena (NASDAQ:PRTA) Downgraded by Jefferies Financial Group to “Hold”: Prothena (NASDAQ:PRTA – Get Free Report) was downgraded by stock analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a report issued on Tuesday, Marketbeat Ratings reports. They presently have a $6.00 price target on the biotechnology company’s stock. Jefferies Financial Group’s target price indicates a potential upside of 30.43% […] - 2025-05-29 03:02:58
JMP Securities Lowers Prothena (NASDAQ:PRTA) Price Target to $29.00: Prothena (NASDAQ:PRTA – Get Free Report) had its target price cut by JMP Securities from $78.00 to $29.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has a “market outperform” rating on the biotechnology company’s stock. A number of other equities analysts have also commented on the company. Wall Street Zen raised Prothena […] - 2025-05-29 03:02:57
Prothena (NASDAQ:PRTA) Rating Lowered to Neutral at Cantor Fitzgerald: Prothena (NASDAQ:PRTA – Get Free Report) was downgraded by research analysts at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating in a research report issued to clients and investors on Tuesday, MarketBeat reports. Several other equities research analysts have also recently issued reports on PRTA. Royal Bank of Canada lowered their price objective […] - 2025-05-29 03:02:53
HC Wainwright Cuts Prothena (NASDAQ:PRTA) Price Target to $14.00: Prothena (NASDAQ:PRTA – Get Free Report) had its price objective decreased by analysts at HC Wainwright from $30.00 to $14.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 204.35% from the company’s current […] - 2025-05-29 02:15:04
Piper Sandler Has Lowered Expectations for Prothena (NASDAQ:PRTA) Stock Price: Prothena (NASDAQ:PRTA – Free Report) had its target price decreased by Piper Sandler from $110.00 to $81.00 in a research report released on Tuesday morning,Benzinga reports. Piper Sandler currently has an overweight rating on the biotechnology company’s stock. A number of other research firms have also commented on PRTA. Oppenheimer lowered Prothena from an “outperform” […] - 2025-05-28 04:46:49
Chardan Capital Has Lowered Expectations for Prothena (NASDAQ:PRTA) Stock Price: Prothena (NASDAQ:PRTA – Free Report) had its price objective lowered by Chardan Capital from $40.00 to $18.00 in a research note released on Tuesday morning,Benzinga reports. Chardan Capital currently has a buy rating on the biotechnology company’s stock. A number of other equities research analysts have also recently commented on the stock. Oppenheimer raised their […] - 2025-05-28 02:52:54
Traders Purchase High Volume of Put Options on Prothena (NASDAQ:PRTA): Prothena Co. plc (NASDAQ:PRTA – Get Free Report) was the recipient of some unusual options trading on Tuesday. Stock traders bought 8,185 put options on the company. This is an increase of approximately 1,210% compared to the average volume of 625 put options. Prothena Price Performance Shares of PRTA stock opened at $4.58 on Wednesday. […] - 2025-05-28 02:06:46
Balyasny Asset Management L.P. Makes New $527,000 Investment in Prothena Co. plc (NASDAQ:PRTA): Balyasny Asset Management L.P. acquired a new position in shares of Prothena Co. plc (NASDAQ:PRTA – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 38,021 shares of the biotechnology company’s stock, valued at approximately $527,000. Balyasny Asset Management L.P. […] - 2025-05-16 05:52:58
Raymond James Financial Inc. Takes Position in Prothena Co. plc (NASDAQ:PRTA): Raymond James Financial Inc. purchased a new stake in shares of Prothena Co. plc (NASDAQ:PRTA – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 13,111 shares of the biotechnology company’s stock, valued at approximately $182,000. Several other institutional investors and […] - 2025-05-13 04:18:47
Prothena (NASDAQ:PRTA) Price Target Lowered to $30.00 at HC Wainwright: Prothena (NASDAQ:PRTA – Free Report) had its price objective reduced by HC Wainwright from $48.00 to $30.00 in a report issued on Friday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. A number of other brokerages have also weighed in on PRTA. Piper Sandler boosted their price objective on shares […] - 2025-05-12 02:44:45
JMP Securities Has Lowered Expectations for Prothena (NASDAQ:PRTA) Stock Price: Prothena (NASDAQ:PRTA – Free Report) had its target price reduced by JMP Securities from $80.00 to $78.00 in a report published on Friday morning,Benzinga reports. They currently have a market outperform rating on the biotechnology company’s stock. A number of other equities research analysts also recently issued reports on the stock. Cantor Fitzgerald reiterated an […] - 2025-05-12 02:44:45
Hsbc Holdings PLC Grows Holdings in Prothena Co. plc (NASDAQ:PRTA): Hsbc Holdings PLC increased its stake in shares of Prothena Co. plc (NASDAQ:PRTA – Free Report) by 60.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 24,179 shares of the biotechnology company’s stock after purchasing an additional 9,101 shares during the period. Hsbc Holdings PLC’s holdings […] - 2025-05-09 05:41:02
Renaissance Technologies LLC Acquires 19,100 Shares of Prothena Co. plc (NASDAQ:PRTA): Renaissance Technologies LLC increased its holdings in shares of Prothena Co. plc (NASDAQ:PRTA – Free Report) by 10.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 201,900 shares of the biotechnology company’s stock after purchasing an additional 19,100 shares during the period. […] - 2025-04-25 05:54:49
Corebridge Financial Inc. Trims Position in Prothena Co. plc (NASDAQ:PRTA): Corebridge Financial Inc. trimmed its position in Prothena Co. plc (NASDAQ:PRTA – Free Report) by 7.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,140 shares of the biotechnology company’s stock after selling 1,596 shares during the quarter. […] - 2025-04-11 05:40:59
Prothena Co. plc (NASDAQ:PRTA) Given Consensus Rating of “Moderate Buy” by Analysts: Prothena Co. plc (NASDAQ:PRTA – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the eight analysts that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among […] - 2025-04-11 04:32:50
KLP Kapitalforvaltning AS Acquires New Shares in Prothena Co. plc (NASDAQ:PRTA): KLP Kapitalforvaltning AS acquired a new position in Prothena Co. plc (NASDAQ:PRTA – Free Report) in the fourth quarter, HoldingsChannel reports. The fund acquired 12,900 shares of the biotechnology company’s stock, valued at approximately $179,000. Several other hedge funds and other institutional investors also recently added to or reduced their stakes in PRTA. Orion Portfolio […] - 2025-04-09 04:28:47

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) PRTA holdings

Date	Number of PRTA Shares Held	Base Market Value of PRTA Shares	Local Market Value of PRTA Shares	Change in PRTA Shares Held	Change in PRTA Base Value	Current Price per PRTA Share Held	Previous Price per PRTA Share Held
2025-12-03 (Wednesday)	38,258	USD 427,342	USD 427,342	0	USD 31,372	USD 11.17	USD 10.35
2025-12-02 (Tuesday)	38,258	USD 395,970	USD 395,970	1,395	USD 17,387	USD 10.35	USD 10.27
2025-12-01 (Monday)	36,863	USD 378,583	USD 378,583	0	USD -17,694	USD 10.27	USD 10.75
2025-11-28 (Friday)	36,863	USD 396,277	USD 396,277	93	USD 12,766	USD 10.75	USD 10.43
2025-11-27 (Thursday)	36,770	USD 383,511	USD 383,511	0	USD 0	USD 10.43	USD 10.43
2025-11-26 (Wednesday)	36,770	USD 383,511	USD 383,511	279	USD 355	USD 10.43	USD 10.5
2025-11-25 (Tuesday)	36,491	USD 383,156	USD 383,156	465	USD 8,486	USD 10.5	USD 10.4
2025-11-24 (Monday)	36,026	USD 374,670	USD 374,670	93	USD -1,908	USD 10.4	USD 10.48
2025-11-21 (Friday)	35,933	USD 376,578	USD 376,578	0	USD 15,451	USD 10.48	USD 10.05
2025-11-20 (Thursday)	35,933	USD 361,127	USD 361,127	-368	USD -1,520	USD 10.05	USD 9.99
2025-11-19 (Wednesday)	36,301	USD 362,647	USD 362,647	92	USD -12,478	USD 9.99	USD 10.36
2025-11-18 (Tuesday)	36,209	USD 375,125	USD 375,125	552	USD 9,641	USD 10.36	USD 10.25
2025-11-17 (Monday)	35,657	USD 365,484	USD 365,484	184	USD 13,237	USD 10.25	USD 9.93

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of PRTA by Blackrock for IE00BYXG2H39

Show aggregate share trades of PRTA

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-12-02 BUY 1,395 10.530 10.140 10.179 USD 14,200 10.86
2025-11-28 BUY 93 10.750* 10.86
2025-11-26 BUY 279 10.590 10.370 10.392 USD 2,899 10.87
2025-11-26 BUY 279 10.590 10.370 10.392 USD 2,899 10.87
2025-11-25 BUY 465 10.620 10.300 10.332 USD 4,804 10.87
2025-11-24 BUY 93 10.900 10.290 10.351 USD 963 10.87
2025-11-20 SELL -368 10.050* 10.88 Profit of 4,003 on sale
2025-11-19 BUY 92 9.990* 10.88
2025-11-18 BUY 552 10.360* 10.88
2025-11-17 BUY 184 10.320 9.750 9.807 USD 1,804 10.89
2025-11-14 BUY 92 10.330 9.930 9.970 USD 917 10.89
2025-11-12 BUY 92 10.850* 10.90
2025-11-10 BUY 91 11.090 10.465 10.527 USD 958 10.90
2025-11-06 BUY 91 10.490 10.015 10.063 USD 916 10.91
2025-11-04 BUY 92 10.560 10.160 10.200 USD 938 10.91
2025-10-30 BUY 460 10.815 10.345 10.392 USD 4,780 10.92
2025-10-29 BUY 184 10.650 10.795 10.781 USD 1,984 10.92
2025-10-22 SELL -364 9.880 10.350 10.303 USD -3,750 10.94 Profit of 233 on sale
2025-10-20 BUY 182 10.370 10.550 10.532 USD 1,917 10.95
2025-10-17 BUY 454 9.920 10.230 10.199 USD 4,630 10.96
2025-10-15 BUY 720 10.660 10.720 10.714 USD 7,714 10.96
2025-10-03 BUY 644 9.920 10.160 10.136 USD 6,528 10.97
2025-10-02 BUY 92 9.990 10.220 10.197 USD 938 10.97
2025-09-30 BUY 184 9.760 9.850 9.841 USD 1,811 10.99
2025-09-26 BUY 184 9.410 9.460 9.455 USD 1,740 11.00
2025-09-25 BUY 184 9.360 9.560 9.540 USD 1,755 11.01
2025-09-18 BUY 94 8.180 8.350 8.333 USD 783 11.04
2025-09-17 BUY 282 8.060 8.385 8.353 USD 2,355 11.06
2025-08-20 SELL -368 8.520 8.595 8.588 USD -3,160 11.12 Profit of 932 on sale
2025-07-30 BUY 364 6.880 7.330 7.285 USD 2,652 11.25
2025-07-17 SELL -184 6.470 6.600 6.587 USD -1,212 11.53 Profit of 909 on sale
2025-07-11 SELL -744 6.400 6.520 6.508 USD -4,842 11.67 Profit of 3,839 on sale
2025-07-07 BUY 279 6.290 6.470 6.452 USD 1,800 11.81
2025-07-02 BUY 5,115 6.320 6.585 6.559 USD 33,547 11.89
2025-06-11 BUY 188 5.100 5.390 5.361 USD 1,008 12.28
2025-06-10 BUY 188 5.260 5.450 5.431 USD 1,021 12.33
2025-06-04 SELL -94 4.880 4.880 4.880 USD -459 12.55 Profit of 721 on sale
2025-04-23 BUY 92 9.590 10.070 10.022 USD 922 14.18
2025-04-10 SELL -736 9.690 10.155 10.108 USD -7,440 14.65 Profit of 3,341 on sale
2025-04-08 SELL -91 10.480 11.500 11.398 USD -1,037 14.75 Profit of 305 on sale
2025-04-07 SELL -91 10.840 11.280 11.236 USD -1,022 14.79 Profit of 324 on sale
2025-04-04 SELL -460 10.860 11.370 11.319 USD -5,207 14.84 Profit of 1,619 on sale
2025-04-01 BUY 376 11.740 12.448 12.377 USD 4,654 14.91
2025-03-31 SELL -276 12.375 12.705 12.672 USD -3,497 14.94 Profit of 626 on sale
2025-03-21 BUY 1,757 12.970 12.990 12.988 USD 22,820 15.09
2025-03-14 SELL -1,392 13.740 14.340 14.280 USD -19,878 15.22 Profit of 1,305 on sale
2025-03-07 SELL -172 15.270 15.626 15.590 USD -2,682 15.29 Loss of -52 on sale
2025-03-04 SELL -86 15.060 15.510 15.465 USD -1,330 15.30 Loss of -14 on sale
2025-02-25 BUY 174 14.630 15.390 15.314 USD 2,665 15.33
2025-02-19 SELL -86 14.980 15.075 15.065 USD -1,296 15.34 Profit of 24 on sale
2025-02-13 BUY 258 13.890 13.920 13.917 USD 3,591 15.44
2025-02-12 BUY 86 13.820 13.920 13.910 USD 1,196 15.48
2025-02-11 BUY 344 13.790 14.110 14.078 USD 4,843 15.51
2024-12-30 SELL -2,757 14.880 15.250 15.213 USD -41,942 15.85 Profit of 1,743 on sale
2024-11-18 SELL -1,383 13.510 14.155 14.090 USD -19,487 17.07 Profit of 4,115 on sale
2024-11-08 SELL -92 17.700 17.920 17.898 USD -1,647 17.00 Loss of -83 on sale
2024-10-21 SELL -93 16.500 17.030 16.977 USD -1,579 0.00 Loss of -1,579 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-12-02	BUY	1,395	10.530	10.140	10.179	USD 14,200	10.86
2025-11-28	BUY	93			10.750*		10.86
2025-11-26	BUY	279	10.590	10.370	10.392	USD 2,899	10.87
2025-11-26	BUY	279	10.590	10.370	10.392	USD 2,899	10.87
2025-11-25	BUY	465	10.620	10.300	10.332	USD 4,804	10.87
2025-11-24	BUY	93	10.900	10.290	10.351	USD 963	10.87
2025-11-20	SELL	-368			10.050*		10.88 Profit of 4,003 on sale
2025-11-19	BUY	92			9.990*		10.88
2025-11-18	BUY	552			10.360*		10.88
2025-11-17	BUY	184	10.320	9.750	9.807	USD 1,804	10.89
2025-11-14	BUY	92	10.330	9.930	9.970	USD 917	10.89
2025-11-12	BUY	92			10.850*		10.90
2025-11-10	BUY	91	11.090	10.465	10.527	USD 958	10.90
2025-11-06	BUY	91	10.490	10.015	10.063	USD 916	10.91
2025-11-04	BUY	92	10.560	10.160	10.200	USD 938	10.91
2025-10-30	BUY	460	10.815	10.345	10.392	USD 4,780	10.92
2025-10-29	BUY	184	10.650	10.795	10.781	USD 1,984	10.92
2025-10-22	SELL	-364	9.880	10.350	10.303	USD -3,750	10.94 Profit of 233 on sale
2025-10-20	BUY	182	10.370	10.550	10.532	USD 1,917	10.95
2025-10-17	BUY	454	9.920	10.230	10.199	USD 4,630	10.96
2025-10-15	BUY	720	10.660	10.720	10.714	USD 7,714	10.96
2025-10-03	BUY	644	9.920	10.160	10.136	USD 6,528	10.97
2025-10-02	BUY	92	9.990	10.220	10.197	USD 938	10.97
2025-09-30	BUY	184	9.760	9.850	9.841	USD 1,811	10.99
2025-09-26	BUY	184	9.410	9.460	9.455	USD 1,740	11.00
2025-09-25	BUY	184	9.360	9.560	9.540	USD 1,755	11.01
2025-09-18	BUY	94	8.180	8.350	8.333	USD 783	11.04
2025-09-17	BUY	282	8.060	8.385	8.353	USD 2,355	11.06
2025-08-20	SELL	-368	8.520	8.595	8.588	USD -3,160	11.12 Profit of 932 on sale
2025-07-30	BUY	364	6.880	7.330	7.285	USD 2,652	11.25
2025-07-17	SELL	-184	6.470	6.600	6.587	USD -1,212	11.53 Profit of 909 on sale
2025-07-11	SELL	-744	6.400	6.520	6.508	USD -4,842	11.67 Profit of 3,839 on sale
2025-07-07	BUY	279	6.290	6.470	6.452	USD 1,800	11.81
2025-07-02	BUY	5,115	6.320	6.585	6.559	USD 33,547	11.89
2025-06-11	BUY	188	5.100	5.390	5.361	USD 1,008	12.28
2025-06-10	BUY	188	5.260	5.450	5.431	USD 1,021	12.33
2025-06-04	SELL	-94	4.880	4.880	4.880	USD -459	12.55 Profit of 721 on sale
2025-04-23	BUY	92	9.590	10.070	10.022	USD 922	14.18
2025-04-10	SELL	-736	9.690	10.155	10.108	USD -7,440	14.65 Profit of 3,341 on sale
2025-04-08	SELL	-91	10.480	11.500	11.398	USD -1,037	14.75 Profit of 305 on sale
2025-04-07	SELL	-91	10.840	11.280	11.236	USD -1,022	14.79 Profit of 324 on sale
2025-04-04	SELL	-460	10.860	11.370	11.319	USD -5,207	14.84 Profit of 1,619 on sale
2025-04-01	BUY	376	11.740	12.448	12.377	USD 4,654	14.91
2025-03-31	SELL	-276	12.375	12.705	12.672	USD -3,497	14.94 Profit of 626 on sale
2025-03-21	BUY	1,757	12.970	12.990	12.988	USD 22,820	15.09
2025-03-14	SELL	-1,392	13.740	14.340	14.280	USD -19,878	15.22 Profit of 1,305 on sale
2025-03-07	SELL	-172	15.270	15.626	15.590	USD -2,682	15.29 Loss of -52 on sale
2025-03-04	SELL	-86	15.060	15.510	15.465	USD -1,330	15.30 Loss of -14 on sale
2025-02-25	BUY	174	14.630	15.390	15.314	USD 2,665	15.33
2025-02-19	SELL	-86	14.980	15.075	15.065	USD -1,296	15.34 Profit of 24 on sale
2025-02-13	BUY	258	13.890	13.920	13.917	USD 3,591	15.44
2025-02-12	BUY	86	13.820	13.920	13.910	USD 1,196	15.48
2025-02-11	BUY	344	13.790	14.110	14.078	USD 4,843	15.51
2024-12-30	SELL	-2,757	14.880	15.250	15.213	USD -41,942	15.85 Profit of 1,743 on sale
2024-11-18	SELL	-1,383	13.510	14.155	14.090	USD -19,487	17.07 Profit of 4,115 on sale
2024-11-08	SELL	-92	17.700	17.920	17.898	USD -1,647	17.00 Loss of -83 on sale
2024-10-21	SELL	-93	16.500	17.030	16.977	USD -1,579	0.00 Loss of -1,579 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of PRTA

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	108,317	0	182,193	59.5%
2025-09-18	65,546	0	159,084	41.2%
2025-09-17	88,134	851	183,394	48.1%
2025-09-16	56,737	0	121,371	46.7%
2025-09-15	120,935	188	321,912	37.6%
2025-09-12	79,607	0	177,443	44.9%
2025-09-11	95,374	0	287,701	33.2%
2025-09-10	56,286	0	176,090	32.0%
2025-09-09	102,797	200	405,123	25.4%
2025-09-08	80,759	0	241,854	33.4%
2025-09-05	79,474	0	527,641	15.1%
2025-09-04	129,893	0	344,758	37.7%
2025-09-03	101,066	0	507,349	19.9%
2025-09-02	79,773	0	480,125	16.6%
2025-08-29	137,287	0	380,237	36.1%
2025-08-28	251,364	27,779	681,662	36.9%
2025-08-27	82,656	202	371,975	22.2%
2025-08-26	63,219	3,211	241,516	26.2%
2025-08-25	87,291	0	233,972	37.3%
2025-08-22	76,154	0	487,311	15.6%
2025-08-21	82,600	0	393,335	21.0%
2025-08-20	56,409	0	225,104	25.1%
2025-08-19	89,014	0	357,093	24.9%
2025-08-18	107,597	0	529,225	20.3%
2025-08-15	70,415	0	445,981	15.8%
2025-08-14	52,592	0	203,477	25.8%
2025-08-13	92,668	0	629,887	14.7%
2025-08-12	111,527	13,821	344,144	32.4%
2025-08-11	110,199	0	376,933	29.2%
2025-08-08	155,275	0	374,244	41.5%
2025-08-07	120,943	0	251,069	48.2%
2025-08-06	339,649	17,356	1,549,642	21.9%
2025-08-05	251,734	19,116	638,388	39.4%
2025-08-04	113,265	64	364,144	31.1%
2025-08-01	130,044	79	324,253	40.1%
2025-07-31	132,258	534	337,231	39.2%
2025-07-30	179,589	6,037	653,059	27.5%
2025-07-29	148,926	111	328,232	45.4%
2025-07-28	110,097	0	308,965	35.6%
2025-07-25	105,656	0	379,134	27.9%
2025-07-24	83,156	0	295,010	28.2%
2025-07-23	106,109	0	341,012	31.1%
2025-07-22	73,032	0	249,701	29.2%
2025-07-21	119,040	0	249,418	47.7%
2025-07-18	124,704	0	299,018	41.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
Issuer	Blackrock
Entity holding fund	iShares IV Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300ZP07LMR36K1T02
ETF Ticker	BTEC(USD) LSE
ETF Ticker	BTEK(GBP) LSE
ETF Ticker	2B70(EUR) F
ETF Ticker	2B70.DE(EUR) CXE
ETF Ticker	BTEC.LS(USD) CXE
ETF Ticker	BTEK.LS(GBP) CXE
ETF Ticker	BTEC.L(GBP) LSE
ETF Ticker	BTEK.L(GBP) LSE